The EDGE Innovation Forum: How Asia-Pacific Biotech Collaboration Is Reshaping Drug Discovery

Executive Summary

The 2nd EDGE Innovation Forum, organized by Jubilant Biosys in San Diego on July 23, 2026, brought together over 50 organizations—including 40 biotechnology companies, 5 large pharmaceutical firms, and 8 investment groups—to accelerate drug discovery through partnerships. The event, featuring an Emerging NewCos Showcase, panel discussions, and networking, reflects the deepening integration of Asia-Pacific contract research, development, and manufacturing organizations (CRDMOs) into global biotech networks. For the Asia-Pacific region, this signals an expanding role in high-value innovation ecosystems, with implications for regional talent development, foreign investment, and cross-border collaboration.

Introduction

In the global biopharmaceutical landscape, Asia-Pacific firms have long been recognized for cost-efficient manufacturing and research services. However, the 2nd EDGE Innovation Forum hosted by Jubilant Biosys—an Indian-headquartered CRDMO—demonstrates a strategic shift toward higher-value partnerships. By convening founders, venture capitalists, and pharmaceutical executives in one of the world’s premier biotech hubs, the forum illustrates how Asia-Pacific organizations are moving beyond service provision to become orchestrators of innovation networks.

Jubilant Biosys, a subsidiary of the Jubilant Bhartia Group, operates over 1,300 scientists across India and France. The company has supported small molecule programs from discovery to commercial manufacturing for more than two decades. The EDGE forum, now in its second year, aims to bridge the gap between scientific innovation and capital deployment—a critical challenge for early-stage biotech companies worldwide.

Main Analysis

The forum’s design reflects a deliberate effort to address funding gaps and partnership inefficiencies in biotech. Key components included:

• Emerging NewCos Showcase: Four biotech startups pitched therapies and platforms to investors and pharmaceutical partners, receiving strategic feedback.
• Keynote Address: Deborah Nguyen, Operating Partner at Red Tree Venture Labs, discussed the evolving landscape of venture creation in biotech.
• Panel Discussions: Experts from firms such as Foresite Capital, Curie Bio, LYZZ Capital, Rezo Therapeutics, and Numerion Labs explored themes around scientific innovation, capital deployment, and new partnership models.

Senior leaders from Jubilant Biosys and the Jubilant Bhartia Group, including Shantanu Jha (Group CHRO) and Prasant Deb (SVP & Site Head), actively participated, signaling the company’s executive commitment to global outreach.

The forum’s location in San Diego, home to a dense concentration of biotech firms and investors, is strategic. It allows Jubilant to position itself as a partner of choice for Western biotechs seeking scalable research and manufacturing capabilities in Asia-Pacific. Conversely, it offers Asia-Pacific start-ups exposure to global capital and commercialization pathways.

Regional Impact

The EDGE Innovation Forum has several implications for the Asia-Pacific region:

• Economic Growth: By facilitating partnerships, such forums enhance the flow of foreign direct investment (FDI) into Asia-Pacific CRDMOs and biotech start-ups. Jubilant’s expansion of its global network could attract more R&D investment to India and other regional hubs.
• Business Competitiveness: Asian CRDMOs are increasingly competing not just on cost but on innovation. Events like EDGE help elevate their brand as strategic partners rather than mere service providers.
• Industrial Development: The forum highlights the maturation of India’s drug discovery ecosystem, which now generates intellectual property and platforms worthy of global attention.
• Trade Integration: Cross-border collaboration in biotech strengthens supply chain resilience and knowledge exchange between Asia-Pacific and North America, a key market.
• Innovation Ecosystems: The showcase model can be replicated across the region to nurture early-stage biotech companies, improving access to capital and expertise.
• Employment: Growth in high-end biotech services creates demand for skilled scientists and managers, driving talent development in India and elsewhere.
• Regional Cooperation: While the forum is bilateral (India–US), it sets a precedent for multi-country collaboration within Asia-Pacific itself – for example, involving Japanese or Singaporean firms in future editions.

Strategic Insights

For business leaders and investors, the EDGE forum offers actionable insights:

• Business Opportunities: Asia-Pacific CRDMOs are well-positioned to capture a larger share of global biotech outsourcing, especially as Western firms seek cost-effective, high-quality partners. Jubilant’s proactive matching of start-ups with investors is a model others may emulate.
• Corporate Strategy: Biotech companies should consider partnering with Asia-Pacific firms not just for manufacturing but for co-development of novel therapies. The forum demonstrates that such partnerships can be facilitated through dedicated networking platforms.
• Investment Implications: Venture capital firms looking to de-risk early-stage investments may benefit from co-investing with CRDMOs that can provide in-kind research services, reducing cash burn for portfolio companies.
• Policy Considerations: Governments in Asia-Pacific should support the creation of similar forums to boost their innovation ecosystems. Tax incentives, infrastructure support, and streamlined regulations for cross-border clinical trials could amplify the impact.
• Emerging Industries: The use of artificial intelligence and machine learning in drug discovery, a key theme in the biotech sector, could be accelerated through partnerships initiated at such events.
• Competitive Risks: As Asia-Pacific firms move up the value chain, they may face intellectual property challenges and increased competition from domestic start-ups in the same markets.
• Geopolitical Business Implications: With US–China tensions affecting biotech collaborations, India emerges as a neutral, trusted partner, making forums like EDGE geopolitically significant.

Future Outlook

Looking ahead to the next 3–5 years, the EDGE forum and similar initiatives are likely to reshape Asia-Pacific’s biotech landscape:

• Expansion of Platforms: Jubilant may expand the EDGE forum to include participants from other Asia-Pacific countries, creating a truly regional innovation network. This could lead to an Asia-Pacific biotech alliance for cross-border research.
• Increased Investment: As success stories emerge from such forums, venture capital flows to Asia-Pacific biotech will likely increase. The region’s share of global biotech VC funding, currently modest, could grow significantly.
• Digital Transformation: The integration of digital tools in drug discovery—artificial intelligence, big data analytics, and cloud computing—will become central to partnership discussions, with Asia-Pacific firms offering both data science talent and research capabilities.
• Policy Evolution: Governments may introduce targeted policies to support biotech hubs, such as India’s “Pharma Vision 2047” or similar initiatives in Southeast Asia, to build on the momentum of global partnerships.
• Supply Chain Resilience: The COVID-19 pandemic highlighted the risks of concentrated supply chains. Asia-Pacific CRDMOs offer alternative sources for drug development, reducing dependence on a few regions.
• Regional Cooperation: Platforms like EDGE could evolve into multilateral forums under the auspices of ASEAN or APEC, fostering harmonized regulatory standards and joint research programs.

In conclusion, the EDGE Innovation Forum is more than a networking event—it is a bellwether for the evolving role of Asia-Pacific firms in global biotech. As the region’s capabilities expand, such forums will be critical in transforming economic potential into tangible innovations that benefit patients worldwide.

Conclusion

The 2nd EDGE Innovation Forum exemplifies how Asia-Pacific contract research organizations are leveraging global platforms to redefine their strategic position. By connecting capital, science, and execution, Jubilant Biosys is not only advancing its own business interests but also catalyzing a broader shift in the biopharmaceutical industry’s geography of innovation. For the Asia-Pacific region, the long-term dividends include a stronger innovation ecosystem, deeper integration into global value chains, and enhanced competitiveness in one of the world’s most dynamic sectors.